Guerbet LLC

214 Carnegie Center

Suite 300

Princeton, NJ 08540

USA

Phone: 812-333-0059

Fax: 812-333-0084

[email protected]

Visit Website

Product Categories:
Contrast Media Injectors

RELATED CONTENT

With its latest evolution, Guerbet reports that it offers advanced performance features to its Optistar Elite.

Feature | Contrast Media Injectors | By Christine Book

Market Analysis: Vendor Focus on Optimizing Patient Safety and ...

Contrast media injectors are used to inject contrast media or contrast agents to enhance the blood and perfusion in ...

January 17, 2024

ELUCIRE (gadopiclenol) Injection Safety Data Poster Presentation

News | Interventional Radiology

Guerbet to Spotlight Diagnostic and Interventional Solutions at the ...

November 3, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced ...

November 03, 2023

Feature | Radiation Dose Management | By Melinda Taschetta-Millane

5 Trends in Radiation Dose Management

Early-stage detection is key to the prevention of life-threatening diseases; however, limited access to data hinders the ...

September 20, 2023

Guerbet, a global specialist in contrast media and medical imaging solutions, announced the success of its teams at the PI-CAI (Prostate Imaging: Cancer Al) Grand Challenge

News | Prostate Cancer

Guerbet Wins PI-CAI Grand Challenge on Detection of Prostate Cancer

July 19, 2023 — Guerbet, a global specialist in contrast media and medical imaging solutions, announced the success of ...

July 19, 2023

Elucirem, a novel new macrocyclic GBCA for use in contrast-enhanced magnetic resonance imaging (MRI), has the highest relaxivity compared to other non-specific GBCAs (gadolinium-based contrast agents)

News | Contrast Media

Guerbet Announces ACR Committee on Drugs and Contrast Media Classifies ...

May 15, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced that ...

May 15, 2023

First dosage administered at the Hospital of the University of Pennsylvania following FDA approval

News | Contrast Media

Guerbet Announces Commercial Launch and First Patient Dosing of ...

February 16, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced ...

February 16, 2023

Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, will present data on Elucirem (gadopiclenol) injection, Dotarem (gadoterate meglumine) injection and AI solutions at the 2022 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting.

News | Contrast Media

Guerbet to Spotlight the Novel New Drug Elucirem (gadopiclenol) ...

November 26, 2022 — Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging offering a ...

November 26, 2022

Guerbet, a global medical imaging company, has announced that the U.S. Food and Drug Administration (FDA) after priority review, approved Elucirem (Gadopiclenol), a new macrocyclic GBCA for use in contrast-enhanced magnetic resonance imaging (MRI).

News | Contrast Media

Guerbet Announces FDA Approval of Elucirem (Gadopiclenol) for Use in ...

September 21, 2022 – Guerbet, a global medical imaging company, has announced that the U.S. Food and Drug Administration ...

September 21, 2022

Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Centralized Application for Marketing Authorization to the European Medicine Agency (EMA) for Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent (GBCA).

News | Contrast Media

Gadopiclenol Marketing Authorization Dossier Submissions Accepted for ...

April 6, 2022 — Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products ...

April 06, 2022

Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging, announced a recent boom for DOTAREM (gadoterate meglumine) injection.

News | Contrast Media

Medical Imaging Leader Reports Record-Breaking Demand for Gadoterate ...

December 7, 2021 — Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging, announced a recent boom ...

December 07, 2021

Guerbet LLC

You're about to leave ITN

RELATED CONTENT